ClinicalTrials.gg
CompletedNCT02784106Updated Jul 17, 2018Results posted

Safety and Efficacy Study of M2951 in Participants With Rheumatoid Arthritis

A Phase 2 interventional study of Placebo and M2951 in Rheumatoid Arthritis, sponsored by EMD Serono Research & Development Institute, Inc.. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-07-17.

Sponsored by EMD Serono Research & Development Institute, Inc. (part of Merck KGaA, Darmstadt, Germany) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 975 studies in Arthritis, Rheumatoid with a site in United States — 82 open to participants now, 122 under way, 7 of them phase 3. Arthritis, Rheumatoid · United States.

Enrollment
487th of 771
65 · median 120
Started
2016
with 57 others
Phase 2
215 of 975
12 open now
Registered
654th of 975
by date

Among the 975 studies in Arthritis, Rheumatoid with a site in United States, this one is the 487th largest by enrollment of the 771 interventional ones that give a count, is one of 58 that started in 2016, is one of 215 in phase 2, and was the 654th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

82 of the 975 studies in Arthritis, Rheumatoid with a site in United States are open now. Recruiting first, the newest first:

77 more — sign in →

All 82 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 975 studies in Arthritis, Rheumatoid with a site in United States, or all of them as a file.
02

Study summary

M2951 is an investigational drug under evaluation for treatment of autoimmune and inflammatory disorders. The purpose of the study is to assess the efficacy of M2951 in participants with rheumatoid arthritis (RA) currently treated with stable dose of methotrexate (MTX).

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Rheumatoid Arthritis
  • M2951
  • Bruton's Tyrosine Kinase (BTK)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women 18 to 75 years of age at the time of signature
  • Confirmed diagnosis of RA according to 2010 American College of Rheumatology (ACR)/The European League Against Rheumatism (EULAR) RA classification criteria of at least 6 months duration
  • Positive RF and/or anti-CCP (anti-cyclic citrullinated peptide)
  • Persistently active disease defined as greater than equal to (>=) 6 swollen joints (of 66 counted) and >= 6 tender joints (of 68 counted)
  • High-sensitivity C-reactive protein (hsCRP) >= 3.6 milligram per liter (mg/L)
  • Treatment for >= 12 weeks with 10 to 25 mg/week MTX at a stable dose for at least 4 weeks prior to dosing with the medicinal product (IMP) and maintained throughout the trial
  • Women of must use acceptable methods of for 4 weeks prior to randomization, throughout the trial, and for 90 days after the last dose of IMP. For the purposes of this trial
  • Females who are (age-related amenorrhea >= 12 consecutive months and increased follicle-stimulating hormone [FSH] greater than (>) 40 milli international units per milliliter [mIU/mL]), or who have undergone hysterectomy or bilateral oophorectomy are exempt from pregnancy testing. If necessary to confirm postmenopausal status, an FSH will be drawn at Screening
  • Acceptable contraception is defined as use of either 2 barrier methods (eg, female diaphragm and male condom), or 1 barrier method in conjunction with one of the following: spermicide, an intrauterine device, or hormonal contraceptives (implant or oral)
  • Women of childbearing potential must have a negative serum pregnancy test at the Screening Visit and a negative urine pregnancy test at Day 1/randomization before dosing.

Exclusion criteria

Exclusion Criteria:

  • Use of oral > 10 mg daily prednisone equivalent, use of injectable corticosteroids, or change in dose of corticosteroids within 2 weeks prior to Screening or during Screening
  • Initiation or change in dose for nonsteroidal anti-inflammatory drugs (NSAIDs) within 2 weeks prior to Screening
  • Treatment with tofacitinib, other Bruton's Tyrosine Kinase (BTK) inhibitors, or a biologic disease-modifying antirheumatic drug (DMARD; eg, anti-tumor necrosis factor alpha [anti-TNF-α], tocilizumab [anti-interleukin-6 receptor], abatacept [CTLA4-Fc]), or other drugs(sulfasalazine would be acceptable at a stable dose) other than methotrexate within 3 months prior to Screening or during Screening
  • Treatment with anti-CD20 therapy (eg, rituximab) within 12 months prior to Screening or during Screening
  • Immunologic disorder other than Rheumatoid Arthritis (RA), with the exception of secondary Sjogren's syndrome associated with RA, and well-controlled diabetes or thyroid disorder, or any other condition requiring oral, intravenous, intramuscular, or intra-articular corticosteroid therapy
  • Vaccination with live or within 1 month prior to Screening
  • Active, , viral, bacterial, or fungal infection, or any major episode of infection requiring hospitalization or treatment with parenteral anti-infectives within 4 weeks of Screening or during Screening, or completion of oral anti-infectives within 2 weeks before or during Screening, or a history of recurrent infections (ie, 3 or more of the same type of infection in a 12-month rolling period). Vaginal candidiasis, onychomycosis, and genital or oral herpes simplex virus considered by the Investigator to be sufficiently controlled would not be exclusionary
  • History of or positive testing for (HIV), antibody and/or polymerase chain reaction, surface antigen (HBsAg) (+) and/or hepatitis B core total, and/or IgM antibody (+) at Screening
  • History of or current diagnosis of active tuberculosis (TB); undergoing treatment for latent TB infection (LTBI); untreated LTBI (as determined by documented results within 3 months of the Screening Visit of a positive TB skin test with purified protein derivative with induration >= 5 millimeter (mm), a positive QuantiFERON-TB test or positive or borderline T-SPOT [Elispot] test); or positive QuantiFERON-TB test at Screening. Participants with documented completed appropriate LTBI treatment would not be excluded and are not required to be tested
  • Participants with current household contacts with active TB will also be excluded
  • Indeterminate QuantiFERON-TB or T-SPOT tests may be repeated once, and will be considered positive if retest results are positive or indeterminate
  • History of cancer, except adequately treated basal cell or squamous cell carcinomas of the skin (no more than 3 lesions requiring treatment in lifetime) or carcinoma in situ/cervical intraepithelial neoplasia of the uterine cervix, unless considered cured > 5 years
  • Clinically significant abnormality on (ECG), or an active infective process or any other clinically significant abnormality on Screening chest X-ray (CXR) taken within 4 weeks of the first dose, per Investigator opinion. If a CXR has been taken within the previous 3 months and results are available and normal, the CXR does not need to be carried out
  • B cell (CD19) count less than (\<) 50% of the lower limit of normal at Screening
  • Significant cytopenia including \< 1,500/ mm\^3, count \< 100,000/mm\^3, or absolute lymphocyte count \< 1,000/mm\^3
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
65 participants (actual)

Study arms

  • Placebo comparator
    Placebo: Double-Blind Treatment Period

    Drug: Placebo

  • Experimental
    M2951: Double-Blind Treatment Period

    Drug: M2951

  • Experimental
    Placebo/M2951: Open Label Extension Period

    Drug: M2951

  • Experimental
    M2951/M2951: Open Label Extension Period

    Drug: M2951

Interventions

  • DrugPlacebo

    Participants received placebo matched to M2951 twice daily up to Day 84 during the double-blind treatment period.

  • DrugM2951

    Participants received 50 milligrams (mg) M2951 orally twice daily up to Day 84 during the double-blind treatment period.

    Also known as: Evobrutinib

  • DrugM2951

    Participants who received placebo matched to M2951 or M2951 in double-blind treatment period, received 50 mg M2951 orally twice daily up to 26-weeks during the open label extension period.

    Also known as: Evobrutinib

06

What researchers measure

Primary outcomes

  1. Proportion of Participants Who Achieved American College of Rheumatology-20 (ACR20) Response

    ACR 20 response: greater than or equal to (\>=) 20 percent (%) improvement in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) together with \>=20% improvement in at least 3 of the following: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI); and 5) acute phase reactant as measured by high-sensitivity C-reactive protein (hsCRP). Proportion of ACR20 responders = Number of participants with ACR20 response divided by total participants.

    Time frame: Day 84

Secondary outcomes

  1. Mean Change From Baseline in High-Sensitivity C-Reactive Protein (hsCRP) at Day 28

    Mean change in the hsCRP concentration from baseline at Day 28 was reported.

    Time frame: Baseline, Day 28

  2. Proportion of Participants Achieving American College of Rheumatology-50 (ACR50) Response

    ACR 50 response: \>=50% improvement in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) together with \>=50% improvement in at least 3 of the following: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function measured by HAQ-DI; and 5) acute phase reactant as measured by hsCRP. Proportion of ACR50 responders = Number of participants with ACR50 response divided by total participants.

    Time frame: Day 28, Day 56 and Day 84

  3. Proportion of Participants Achieving American College of Rheumatology-70 (ACR70) Response

    ACR 70 response: \>=70% improvement in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) together with \>=70% improvement in at least 3 of the following: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function measured by HAQ-DI; and 5) acute phase reactant as measured by hsCRP. Proportion of ACR70 responders = Number of participants with ACR70 response divided by total participants.

    Time frame: Day 28, Day 56 and Day 84

  4. Mean Change From Baseline in High-Sensitivity C-Reactive Protein (hsCRP) at Day 84

    Mean change in the hsCRP concentration from baseline at Day 84 was reported.

    Time frame: Baseline, Day 84

  5. Mean Change From Baseline in Disease Activity Score Based on a 28 Joint Count High-Sensitivity C-Reactive Protein (DAS28-hsCRP) at Day 28 and 84

    Disease Activity Score (DAS) based on a 28 joint count hsCRP consisted of composite numerical score of following variables: tender joint count (TJC28), swollen joint count (SJC28), hsCRP (mg/mL), and participant's global assessment of disease activity. DAS28-hsCRP was calculated using following formula: DAS28-hsCRP equals to (=) 0.56\*square root (sqrt) (TJC28) plus (+) 0.28\*sqrt (SJC28)+ 0.014\* participant's global assessment of disease activity + 0.36\*natural log(hsCRP+1) +0.96. Scores ranged 1.0-9.4, where lower scores indicated less disease activity.

    Time frame: Baseline, Day 28 and Day 84

  6. Proportion of Participants With Disease Activity Score- High Sensitivity C-Reactive Protein (DAS28-hsCRP) Value Less Than (<) 3.2

    DAS28-hsCRP consisted of composite score of following variables: TJC28, SJC28, hsCRP (mg/mL), and participant's global assessment of disease activity. DAS28-hsCRP was calculated using following formula: DAS28-hsCRP =0.56\* sqrt(TJC28) + 0.28\*sqrt(SJC28)+ 0.014\* participant's global assessment of disease activity + 0.36\*natural log(hsCRP+1) +0.96. Scores ranged 1.0-9.4, where lower scores indicated less disease activity. Proportion of participants with DAS28-hsCRP value \<3.2 were reported.

    Time frame: Day 84

  7. Proportion of Participants With Disease Activity Score- High Sensitivity C-Reactive Protein (DAS28-hsCRP) Value Less Than (<) 2.6

    DAS28 consisted of composite score of following variables: TJC28, SJC28, hsCRP (mg/mL), and participant's global assessment of disease activity. DAS28-hsCRP was calculated using following formula: DAS28-hsCRP =0.56\* sqrt (TJC28) + 0.28\*sqrt (SJC28)+ 0.014\* participant's global assessment of disease activity + 0.36\*natural log(hsCRP+1) +0.96. Scores ranged 1.0-9.4, where lower scores indicated less disease activity. Proportion of participants with DAS28-hsCRP value \<2.6 were reported.

    Time frame: Day 84

  8. Change From Baseline in Erythrocyte Sedimentation Rate (ESR) at Day 28 and 84

    Erythrocyte sedimentation rate (ESR) is a type of blood test that measures how quickly erythrocytes (red blood cells) settle at the bottom of a test tube that contains a blood sample. Higher values indicate inflammation in the body.

    Time frame: Baseline, Day 28 and Day 84

  9. Change From Baseline in Anti-cyclic Citrullinated Peptide (Anti-CCP) Antibody Levels at Day 28 and 84

    Anti-cyclic citrullinated peptide (anti-CCP) is an antibody present in most rheumatoid arthritis participants.

    Time frame: Baseline, Day 28 and Day 84

  10. Change From Baseline in Rheumatoid Factor (RF) at Day 28 and 84

    Rheumatoid Factor is an anti-body present in the blood.

    Time frame: Baseline, Day 28 and Day 84

  11. Change From Baseline in Global Assessment of Disease Activity Based on Visual Analog Scale (VAS) Score at Day 84

    The participant's overall assessment of disease activity was recorded using the 100 millimeter (mm) horizontal visual analog scale (VAS). The scale ranged from 0-100 mm, where 0 indicated no disease activity (symptom free and no arthritis symptoms) and 100 represented maximum disease activity (maximum arthritis disease activity).

    Time frame: Baseline, Day 84

  12. Change From Baseline in Self-assessment of Pain Based on Visual Analog Scale (VAS) Score at Day 84

    The participants were asked to assess their level of pain by marking a vertical tick on a 100 mm horizontal VAS scale. The scale ranged from 0-100 mm, where 0 indicated no pain and 100 indicated worst possible pain.

    Time frame: Baseline, Day 84

  13. Change From Baseline in Self-assessment of Disability Using Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Day 84

    The HAQ-DI questionnaire assessed the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition.

    Time frame: Baseline, Day 84

  14. Change From Baseline in Physician's Global Assessment of Disease Activity Scale Based on Visual Analog Scale (VAS) Score at Day 84

    The Physician's Global Assessment of Disease Activity was recorded using the 100 mm horizontal VAS. Physician rated participant's arthritis disease activity on a scale ranged from 0-100 mm, where 0 indicated no disease activity (no arthritis) and 100 represented maximum disease activity (maximum arthritis).

    Time frame: Baseline, Day 84

  15. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    An Adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent are events between first dose of study drug that were absent before treatment or that worsened relative to pre-treatment state. TEAEs included both Serious TEAEs and non-serious TEAEs.

    Time frame: Baseline up to 16 Weeks

  16. Number of Participants With Treatment Emergent Adverse Events (TEAEs) by Severity

    Grade 3 and 4 TEAES as per National Cancer Institute Common Terminology Criteria for Adverse Experience version 4.03 (NCI-CTCAE v 4.03) were presented. Grade 3 refers to severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care and Activity of daily living (ADL).Grade 4 refers to Life-threatening consequences; where urgent intervention indicated.

    Time frame: Baseline up to 16 Weeks

  17. Number of Participants With Grade 3 or Higher Clinically Significant Abnormality for Hematology, Biochemistry, Urinalysis or Coagulation

    Clinically significant abnormalities for hematology, biochemistry or coagulation were graded with National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.03 toxicity grades, where Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life threatening and Grade 5 = death. Participants with grade 3 or higher were reported.

    Time frame: Baseline up to 16 Weeks

  18. Number of Participants With Clinically Significant Vital Signs Abnormalities

    Vital sign assessment included blood pressure, pulse rate, respiratory rate and temperature. Clinical significance was determined by the investigator.

    Time frame: Baseline up to 16 Weeks

  19. Number of Participants With Clinically Significant 12-lead Electrocardiogram (ECG) Findings

    The 12-lead ECG recordings were obtained after 10 minutes of rest in a semi-supine position. The ECG parameters obtained directly from the computerized 12-lead ECG recordings included rhythm, ventricular rate, PR interval, QRS duration, and QT interval. Clinical significance was determined by the investigator.

    Time frame: Baseline up to 16 Weeks

  20. Plasma Concentration of M2951

    Time frame: Pre-dose at Day 1; 0.25, 0.5, 1.0, 2.0, 4.0, 6.0 hours post-dose at Day 1 and Day 29

  21. Area Under the Concentration-Time Curve From Time Zero to 6 Hours (AUC 0-6h) of M2951

    Time frame: Pre-dose, 0.25, 0.5, 1.0, 2.0, 4.0, 6.0 hours post-dose at Day 1 and Day 29

  22. Maximum Observed Plasma Concentration (Cmax) of M2951

    Time frame: Pre-dose, 0.25, 0.5, 1.0, 2.0, 4.0, 6.0 hours post-dose at Day 1 and Day 29

  23. Plasma Concentration Observed Immediately Before Dosing on Day 29 (Cpre) of M2951

    Time frame: Pre-dose on Day 29

  24. Time to Reach Maximum Plasma Concentration (Tmax) of M2951

    Time frame: Pre-dose, 0.25, 0.5, 1.0, 2.0, 4.0, 6.0 hours post-dose at Day 1 and Day 29

  25. Accumulation Ratio for Area Under the Concentration-Time Curve From Time Zero to 6 Hours (Racc [AUC0-6h]) of M2951

    Accumulation ratio for AUC was calculated as AUC 0-6h, Day 29 divided by AUC 0-6h, Day 1

    Time frame: Pre-dose, 0.25, 0.5, 1.0, 2.0, 4.0, 6.0 hours post-dose at Day 1 and Day 29

  26. Accumulation Ratio for Observed Maximum Plasma Concentration (Racc [Cmax]) of M2951

    Accumulation ratio for Cmax , was calculated as Cmax, Day 29 divided by Cmax, Day1

    Time frame: Pre-dose, 0.25, 0.5, 1.0, 2.0, 4.0, 6.0 hours post-dose at Day 1 and Day 29

  27. Absolute Immunoglobulin Levels at Day 85

    Following immunoglobulin levels were measured: Immunoglobulin A , Immunoglobulin G, Immunoglobulin G Subclass 1, Immunoglobulin G Subclass 2, Immunoglobulin G Subclass 3, Immunoglobulin G Subclass 4, Immunoglobulin M.

    Time frame: Baseline, Day 85

  28. Absolute Change From Baseline in Immunoglobulin Levels at Day 85

    Following immunoglobulin levels were measured: Immunoglobulin A , Immunoglobulin G, Immunoglobulin G Subclass 1, Immunoglobulin G Subclass 2, Immunoglobulin G Subclass 3, Immunoglobulin G Subclass 4, Immunoglobulin M.

    Time frame: Baseline, Day 85

  29. Absolute B-Cell Levels at Day 85

    Time frame: Day 85

  30. Absolute Change From Baseline in B-cell Levels at Day 85

    Time frame: Baseline, Day 85

07

Results

Posted May 30, 2018

Participant flow

Double-Blind Treatment Period (12 Weeks)
Participant flow — Double-Blind Treatment Period (12 Weeks)
MilestonePlacebo: Double-Blind Treatment PeriodM2951: Double-Blind Treatment PeriodPlacebo/M2951: Open-Label Extension PeriodM2951/M2951: Open-Label Extension Period
Started323300
Completed242700
Not completed8600
Withdrew: Adverse event3500
Withdrew: Withdrawal by subject2100
Withdrew: Other2000
Withdrew: Lack of efficacy1000
Open-Label Extension Period (26 Weeks)
Participant flow — Open-Label Extension Period (26 Weeks)
MilestonePlacebo: Double-Blind Treatment PeriodM2951: Double-Blind Treatment PeriodPlacebo/M2951: Open-Label Extension PeriodM2951/M2951: Open-Label Extension Period
Started001821
Completed001519
Not completed0032
Withdrew: Adverse event0021
Withdrew: Lack of efficacy0011

Outcome measures

PrimaryProportion of Participants Who Achieved American College of Rheumatology-20 (ACR20) Response

ACR 20 response: greater than or equal to (\>=) 20 percent (%) improvement in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) together with \>=20% improvement in at least 3 of the following: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI); and 5) acute phase reactant as measured by high-sensitivity C-reactive protein (hsCRP). Proportion of ACR20 responders = Number of participants with ACR20 response divided by total participants.

Time frame:
Day 84
Reported as:
Number · proportion of participants
Proportion of Participants Who Achieved American College of Rheumatology-20 (ACR20) Response
proportion of participantsPlacebo: Double-Blind Treatment PeriodM2951: Double-Blind Treatment Period
Proportion of Participants Who Achieved American College of Rheumatology-20 (ACR20) Response0.420.52
Statistical analysis
  • Placebo: Double-Blind Treatment Period vs M2951: Double-Blind Treatment Period · Difference in proportion of responders: 0.10 · 80% CI -0.07 to 0.25
SecondaryMean Change From Baseline in High-Sensitivity C-Reactive Protein (hsCRP) at Day 28

Mean change in the hsCRP concentration from baseline at Day 28 was reported.

Time frame:
Baseline, Day 28
Reported as:
Mean · milligram/milliliter (mg/mL)
Mean Change From Baseline in High-Sensitivity C-Reactive Protein (hsCRP) at Day 28
milligram/milliliter (mg/mL)Placebo: Double-Blind Treatment PeriodM2951: Double-Blind Treatment Period
Mean Change From Baseline in High-Sensitivity C-Reactive Protein (hsCRP) at Day 28-0.80 ± 2.00-2.72 ± 1.93
Statistical analysis
  • Placebo: Double-Blind Treatment Period vs M2951: Double-Blind Treatment Period · Difference in mean changes: -1.93 · 80% CI -5.54 to 1.69
SecondaryProportion of Participants Achieving American College of Rheumatology-50 (ACR50) Response

ACR 50 response: \>=50% improvement in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) together with \>=50% improvement in at least 3 of the following: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function measured by HAQ-DI; and 5) acute phase reactant as measured by hsCRP. Proportion of ACR50 responders = Number of participants with ACR50 response divided by total participants.

Time frame:
Day 28, Day 56 and Day 84
Reported as:
Number · proportion of participants
Proportion of Participants Achieving American College of Rheumatology-50 (ACR50) Response
proportion of participantsPlacebo: Double-Blind Treatment PeriodM2951: Double-Blind Treatment Period
Day 280.100.06
Day 560.230.18
Day 840.230.21
Statistical analysis
  • Placebo: Double-Blind Treatment Period vs M2951: Double-Blind Treatment Period · Difference in proportion of responders: -0.04 · 80% CI -0.13 to 0.06
  • Placebo: Double-Blind Treatment Period vs M2951: Double-Blind Treatment Period · Difference in proportion of responders: -0.04 · 80% CI -0.18 to 0.09
  • Placebo: Double-Blind Treatment Period vs M2951: Double-Blind Treatment Period · Difference in proportion of responders: -0.01 · 80% CI -0.15 to 0.12
SecondaryProportion of Participants Achieving American College of Rheumatology-70 (ACR70) Response

ACR 70 response: \>=70% improvement in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) together with \>=70% improvement in at least 3 of the following: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function measured by HAQ-DI; and 5) acute phase reactant as measured by hsCRP. Proportion of ACR70 responders = Number of participants with ACR70 response divided by total participants.

Time frame:
Day 28, Day 56 and Day 84
Reported as:
Number · proportion of participants
Proportion of Participants Achieving American College of Rheumatology-70 (ACR70) Response
proportion of participantsPlacebo: Double-Blind Treatment PeriodM2951: Double-Blind Treatment Period
Day 280.000.06
Day 560.030.06
Day 840.130.09
Statistical analysis
  • Placebo: Double-Blind Treatment Period vs M2951: Double-Blind Treatment Period · Difference in proportion of responders: 0.06 · 80% CI 0.01 to 0.14
  • Placebo: Double-Blind Treatment Period vs M2951: Double-Blind Treatment Period · Difference in proportion of responders: 0.03 · 80% CI -0.05 to 0.11
  • Placebo: Double-Blind Treatment Period vs M2951: Double-Blind Treatment Period · Difference in proportion of responders: -0.04 · 80% CI -0.15 to 0.07
SecondaryMean Change From Baseline in High-Sensitivity C-Reactive Protein (hsCRP) at Day 84

Mean change in the hsCRP concentration from baseline at Day 84 was reported.

Time frame:
Baseline, Day 84
Reported as:
Mean · mg/mL
Mean Change From Baseline in High-Sensitivity C-Reactive Protein (hsCRP) at Day 84
mg/mLPlacebo: Double-Blind Treatment PeriodM2951: Double-Blind Treatment Period
Mean Change From Baseline in High-Sensitivity C-Reactive Protein (hsCRP) at Day 84-2.14 ± 2.20-3.54 ± 2.13
Statistical analysis
  • Placebo: Double-Blind Treatment Period vs M2951: Double-Blind Treatment Period · Difference in mean changes: -1.40 · 80% CI -5.37 to 2.58
SecondaryMean Change From Baseline in Disease Activity Score Based on a 28 Joint Count High-Sensitivity C-Reactive Protein (DAS28-hsCRP) at Day 28 and 84

Disease Activity Score (DAS) based on a 28 joint count hsCRP consisted of composite numerical score of following variables: tender joint count (TJC28), swollen joint count (SJC28), hsCRP (mg/mL), and participant's global assessment of disease activity. DAS28-hsCRP was calculated using following formula: DAS28-hsCRP equals to (=) 0.56\*square root (sqrt) (TJC28) plus (+) 0.28\*sqrt (SJC28)+ 0.014\* participant's global assessment of disease activity + 0.36\*natural log(hsCRP+1) +0.96. Scores ranged 1.0-9.4, where lower scores indicated less disease activity.

Time frame:
Baseline, Day 28 and Day 84
Reported as:
Mean · units on a scale
Mean Change From Baseline in Disease Activity Score Based on a 28 Joint Count High-Sensitivity C-Reactive Protein (DAS28-hsCRP) at Day 28 and 84
units on a scalePlacebo: Double-Blind Treatment PeriodM2951: Double-Blind Treatment Period
Change at Day 28-0.79 ± 0.14-0.87 ± 0.13
Change at Day 84-1.35 ± 0.20-1.28 ± 0.19
Statistical analysis
  • Placebo: Double-Blind Treatment Period vs M2951: Double-Blind Treatment Period · Difference in mean changes: -0.08 · 80% CI -0.33 to 0.16
  • Placebo: Double-Blind Treatment Period vs M2951: Double-Blind Treatment Period · Difference in mean changes: 0.07 · 80% CI -0.29 to 0.43
SecondaryProportion of Participants With Disease Activity Score- High Sensitivity C-Reactive Protein (DAS28-hsCRP) Value Less Than (<) 3.2

DAS28-hsCRP consisted of composite score of following variables: TJC28, SJC28, hsCRP (mg/mL), and participant's global assessment of disease activity. DAS28-hsCRP was calculated using following formula: DAS28-hsCRP =0.56\* sqrt(TJC28) + 0.28\*sqrt(SJC28)+ 0.014\* participant's global assessment of disease activity + 0.36\*natural log(hsCRP+1) +0.96. Scores ranged 1.0-9.4, where lower scores indicated less disease activity. Proportion of participants with DAS28-hsCRP value \<3.2 were reported.

Time frame:
Day 84
Reported as:
Number · proportion of participants
Proportion of Participants With Disease Activity Score- High Sensitivity C-Reactive Protein (DAS28-hsCRP) Value Less Than (<) 3.2
proportion of participantsPlacebo: Double-Blind Treatment PeriodM2951: Double-Blind Treatment Period
Proportion of Participants With Disease Activity Score- High Sensitivity C-Reactive Protein (DAS28-hsCRP) Value Less Than (<) 3.20.130.21
Statistical analysis
  • Placebo: Double-Blind Treatment Period vs M2951: Double-Blind Treatment Period · Difference in proportion of participants: 0.08 · 80% CI -0.04 to 0.21
SecondaryProportion of Participants With Disease Activity Score- High Sensitivity C-Reactive Protein (DAS28-hsCRP) Value Less Than (<) 2.6

DAS28 consisted of composite score of following variables: TJC28, SJC28, hsCRP (mg/mL), and participant's global assessment of disease activity. DAS28-hsCRP was calculated using following formula: DAS28-hsCRP =0.56\* sqrt (TJC28) + 0.28\*sqrt (SJC28)+ 0.014\* participant's global assessment of disease activity + 0.36\*natural log(hsCRP+1) +0.96. Scores ranged 1.0-9.4, where lower scores indicated less disease activity. Proportion of participants with DAS28-hsCRP value \<2.6 were reported.

Time frame:
Day 84
Reported as:
Number · proportion of participants
Proportion of Participants With Disease Activity Score- High Sensitivity C-Reactive Protein (DAS28-hsCRP) Value Less Than (<) 2.6
proportion of participantsPlacebo: Double-Blind Treatment PeriodM2951: Double-Blind Treatment Period
Proportion of Participants With Disease Activity Score- High Sensitivity C-Reactive Protein (DAS28-hsCRP) Value Less Than (<) 2.60.100.06
Statistical analysis
  • Placebo: Double-Blind Treatment Period vs M2951: Double-Blind Treatment Period · Difference in proportion of participants: -0.04 · 80% CI -0.13 to 0.06
SecondaryChange From Baseline in Erythrocyte Sedimentation Rate (ESR) at Day 28 and 84

Erythrocyte sedimentation rate (ESR) is a type of blood test that measures how quickly erythrocytes (red blood cells) settle at the bottom of a test tube that contains a blood sample. Higher values indicate inflammation in the body.

Time frame:
Baseline, Day 28 and Day 84
Reported as:
Mean · millimeter/hour (mm/hour)
Change From Baseline in Erythrocyte Sedimentation Rate (ESR) at Day 28 and 84
millimeter/hour (mm/hour)Placebo: Double-Blind Treatment PeriodM2951: Double-Blind Treatment Period
Change at Day 28-3 ± 36.9-7 ± 22.1
Change at Day 84-3 ± 21.0-9 ± 21.1
SecondaryChange From Baseline in Anti-cyclic Citrullinated Peptide (Anti-CCP) Antibody Levels at Day 28 and 84

Anti-cyclic citrullinated peptide (anti-CCP) is an antibody present in most rheumatoid arthritis participants.

Time frame:
Baseline, Day 28 and Day 84
Reported as:
Mean · units/milliliter
Change From Baseline in Anti-cyclic Citrullinated Peptide (Anti-CCP) Antibody Levels at Day 28 and 84
units/milliliterPlacebo: Double-Blind Treatment PeriodM2951: Double-Blind Treatment Period
Change at Day 28168 ± 991.1-138 ± 720.9
Change at Day 84301 ± 1282.6-396 ± 736.8
SecondaryChange From Baseline in Rheumatoid Factor (RF) at Day 28 and 84

Rheumatoid Factor is an anti-body present in the blood.

Time frame:
Baseline, Day 28 and Day 84
Reported as:
Mean · kiloUnit/Liter (kU/L)
Change From Baseline in Rheumatoid Factor (RF) at Day 28 and 84
kiloUnit/Liter (kU/L)Placebo: Double-Blind Treatment PeriodM2951: Double-Blind Treatment Period
Change at Day 28-30 ± 124.2-7 ± 59.7
Change at Day 84-34 ± 132.1-26 ± 79.9
SecondaryChange From Baseline in Global Assessment of Disease Activity Based on Visual Analog Scale (VAS) Score at Day 84

The participant's overall assessment of disease activity was recorded using the 100 millimeter (mm) horizontal visual analog scale (VAS). The scale ranged from 0-100 mm, where 0 indicated no disease activity (symptom free and no arthritis symptoms) and 100 represented maximum disease activity (maximum arthritis disease activity).

Time frame:
Baseline, Day 84
Reported as:
Mean · millimeter
Change From Baseline in Global Assessment of Disease Activity Based on Visual Analog Scale (VAS) Score at Day 84
millimeterPlacebo: Double-Blind Treatment PeriodM2951: Double-Blind Treatment Period
Change From Baseline in Global Assessment of Disease Activity Based on Visual Analog Scale (VAS) Score at Day 84-21 ± 23.5-24 ± 24.6
SecondaryChange From Baseline in Self-assessment of Pain Based on Visual Analog Scale (VAS) Score at Day 84

The participants were asked to assess their level of pain by marking a vertical tick on a 100 mm horizontal VAS scale. The scale ranged from 0-100 mm, where 0 indicated no pain and 100 indicated worst possible pain.

Time frame:
Baseline, Day 84
Reported as:
Mean · millimeter
Change From Baseline in Self-assessment of Pain Based on Visual Analog Scale (VAS) Score at Day 84
millimeterPlacebo: Double-Blind Treatment PeriodM2951: Double-Blind Treatment Period
Change From Baseline in Self-assessment of Pain Based on Visual Analog Scale (VAS) Score at Day 84-19 ± 21.8-22 ± 22.0
SecondaryChange From Baseline in Self-assessment of Disability Using Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Day 84

The HAQ-DI questionnaire assessed the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition.

Time frame:
Baseline, Day 84
Reported as:
Mean · units on a scale
Change From Baseline in Self-assessment of Disability Using Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Day 84
units on a scalePlacebo: Double-Blind Treatment PeriodM2951: Double-Blind Treatment Period
Change From Baseline in Self-assessment of Disability Using Health Assessment Questionnaire - Disability Index (HAQ-DI) Score at Day 84-0.3 ± 0.44-0.3 ± 0.41
SecondaryChange From Baseline in Physician's Global Assessment of Disease Activity Scale Based on Visual Analog Scale (VAS) Score at Day 84

The Physician's Global Assessment of Disease Activity was recorded using the 100 mm horizontal VAS. Physician rated participant's arthritis disease activity on a scale ranged from 0-100 mm, where 0 indicated no disease activity (no arthritis) and 100 represented maximum disease activity (maximum arthritis).

Time frame:
Baseline, Day 84
Reported as:
Mean · millimeter
Change From Baseline in Physician's Global Assessment of Disease Activity Scale Based on Visual Analog Scale (VAS) Score at Day 84
millimeterPlacebo: Double-Blind Treatment PeriodM2951: Double-Blind Treatment Period
Change From Baseline in Physician's Global Assessment of Disease Activity Scale Based on Visual Analog Scale (VAS) Score at Day 84-33 ± 20.3-30 ± 22.7
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

An Adverse event (AE) was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug. A serious adverse event (SAE) was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent are events between first dose of study drug that were absent before treatment or that worsened relative to pre-treatment state. TEAEs included both Serious TEAEs and non-serious TEAEs.

Time frame:
Baseline up to 16 Weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsPlacebo: Double-Blind Treatment PeriodM2951: Double-Blind Treatment Period
TEAEs1622
SAEs01
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) by Severity

Grade 3 and 4 TEAES as per National Cancer Institute Common Terminology Criteria for Adverse Experience version 4.03 (NCI-CTCAE v 4.03) were presented. Grade 3 refers to severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care and Activity of daily living (ADL).Grade 4 refers to Life-threatening consequences; where urgent intervention indicated.

Time frame:
Baseline up to 16 Weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) by Severity
ParticipantsPlacebo: Double-Blind Treatment PeriodM2951: Double-Blind Treatment Period
NCI-CTCAE Severity grade >=323
NCI-CTCAE Severity grade >=401
SecondaryNumber of Participants With Grade 3 or Higher Clinically Significant Abnormality for Hematology, Biochemistry, Urinalysis or Coagulation

Clinically significant abnormalities for hematology, biochemistry or coagulation were graded with National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.03 toxicity grades, where Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life threatening and Grade 5 = death. Participants with grade 3 or higher were reported.

Time frame:
Baseline up to 16 Weeks
Reported as:
Count of participants · Participants
Number of Participants With Grade 3 or Higher Clinically Significant Abnormality for Hematology, Biochemistry, Urinalysis or Coagulation
ParticipantsPlacebo: Double-Blind Treatment PeriodM2951: Double-Blind Treatment Period
Hematology20
Biochemistry42
Coagulation00
Urinalysis00
SecondaryNumber of Participants With Clinically Significant Vital Signs Abnormalities

Vital sign assessment included blood pressure, pulse rate, respiratory rate and temperature. Clinical significance was determined by the investigator.

Time frame:
Baseline up to 16 Weeks
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Vital Signs Abnormalities
ParticipantsPlacebo: Double-Blind Treatment PeriodM2951: Double-Blind Treatment Period
Number of Participants With Clinically Significant Vital Signs Abnormalities00
SecondaryNumber of Participants With Clinically Significant 12-lead Electrocardiogram (ECG) Findings

The 12-lead ECG recordings were obtained after 10 minutes of rest in a semi-supine position. The ECG parameters obtained directly from the computerized 12-lead ECG recordings included rhythm, ventricular rate, PR interval, QRS duration, and QT interval. Clinical significance was determined by the investigator.

Time frame:
Baseline up to 16 Weeks
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant 12-lead Electrocardiogram (ECG) Findings
ParticipantsPlacebo: Double-Blind Treatment PeriodM2951: Double-Blind Treatment Period
Number of Participants With Clinically Significant 12-lead Electrocardiogram (ECG) Findings00
SecondaryPlasma Concentration of M2951
Time frame:
Pre-dose at Day 1; 0.25, 0.5, 1.0, 2.0, 4.0, 6.0 hours post-dose at Day 1 and Day 29
Reported as:
Mean · nanogram per milliliter (ng/mL)
Plasma Concentration of M2951
nanogram per milliliter (ng/mL)M2951: Double-Blind Treatment Period
Day 1: Pre-Dose:0.00 ± NA
Day 1: 0.25 hours post-dose10.3 ± 23.37
Day 1: 0.5 hours post-dose80.5 ± 136.9
Day 1: 1 hour post-dose160 ± 219.7
Day 1: 2 hours post-dose125 ± 111.9
Day 1: 4 hours post-dose47.3 ± 41.62
Day 1: 6 hours post-dose23.7 ± 20.92
Day 29: 0.25 hours post-dose22.0 ± 71.57
Day 29: 0.5 hours post-dose88.4 ± 114.1
Day 29: 1 hour post-dose120 ± 107.2
Day 29: 2 hours post-dose82.3 ± 53.82
Day 29: 4 hours post-dose62.1 ± 82.39
Day 29: 6 hour post-dose37.2 ± 43.96
SecondaryArea Under the Concentration-Time Curve From Time Zero to 6 Hours (AUC 0-6h) of M2951
Time frame:
Pre-dose, 0.25, 0.5, 1.0, 2.0, 4.0, 6.0 hours post-dose at Day 1 and Day 29
Reported as:
Mean · hours*nanogram/milliliter
Area Under the Concentration-Time Curve From Time Zero to 6 Hours (AUC 0-6h) of M2951
hours*nanogram/milliliterM2951: Double-Blind Treatment Period
Day 1431 ± 390.9
Day 29414 ± 268.4
SecondaryMaximum Observed Plasma Concentration (Cmax) of M2951
Time frame:
Pre-dose, 0.25, 0.5, 1.0, 2.0, 4.0, 6.0 hours post-dose at Day 1 and Day 29
Reported as:
Mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) of M2951
ng/mLM2951: Double-Blind Treatment Period
Day 1206 ± 214.7
Day 29171 ± 130.1
SecondaryPlasma Concentration Observed Immediately Before Dosing on Day 29 (Cpre) of M2951
Time frame:
Pre-dose on Day 29
Reported as:
Mean · ng/mL
Plasma Concentration Observed Immediately Before Dosing on Day 29 (Cpre) of M2951
ng/mLM2951: Double-Blind Treatment Period
Plasma Concentration Observed Immediately Before Dosing on Day 29 (Cpre) of M29515.47 ± 4.735
SecondaryTime to Reach Maximum Plasma Concentration (Tmax) of M2951
Time frame:
Pre-dose, 0.25, 0.5, 1.0, 2.0, 4.0, 6.0 hours post-dose at Day 1 and Day 29
Reported as:
Median · hour
Time to Reach Maximum Plasma Concentration (Tmax) of M2951
hourM2951: Double-Blind Treatment Period
Day 11.00 (0.50 to 4.00)
Day 291.00 (0.50 to 6.00)
SecondaryAccumulation Ratio for Area Under the Concentration-Time Curve From Time Zero to 6 Hours (Racc [AUC0-6h]) of M2951

Accumulation ratio for AUC was calculated as AUC 0-6h, Day 29 divided by AUC 0-6h, Day 1

Time frame:
Pre-dose, 0.25, 0.5, 1.0, 2.0, 4.0, 6.0 hours post-dose at Day 1 and Day 29
Reported as:
Mean · ratio
Accumulation Ratio for Area Under the Concentration-Time Curve From Time Zero to 6 Hours (Racc [AUC0-6h]) of M2951
ratioM2951: Double-Blind Treatment Period
Accumulation Ratio for Area Under the Concentration-Time Curve From Time Zero to 6 Hours (Racc [AUC0-6h]) of M29511.38 ± 1.134
SecondaryAccumulation Ratio for Observed Maximum Plasma Concentration (Racc [Cmax]) of M2951

Accumulation ratio for Cmax , was calculated as Cmax, Day 29 divided by Cmax, Day1

Time frame:
Pre-dose, 0.25, 0.5, 1.0, 2.0, 4.0, 6.0 hours post-dose at Day 1 and Day 29
Reported as:
Mean · ratio
Accumulation Ratio for Observed Maximum Plasma Concentration (Racc [Cmax]) of M2951
ratioM2951: Double-Blind Treatment Period
Accumulation Ratio for Observed Maximum Plasma Concentration (Racc [Cmax]) of M29511.52 ± 1.929
SecondaryAbsolute Immunoglobulin Levels at Day 85

Following immunoglobulin levels were measured: Immunoglobulin A , Immunoglobulin G, Immunoglobulin G Subclass 1, Immunoglobulin G Subclass 2, Immunoglobulin G Subclass 3, Immunoglobulin G Subclass 4, Immunoglobulin M.

Time frame:
Baseline, Day 85
Reported as:
Mean · gram/Liter
Absolute Immunoglobulin Levels at Day 85
gram/LiterPlacebo: Double-Blind Treatment PeriodM2951: Double-Blind Treatment Period
Immunoglobulin A2.09 ± 0.9682.77 ± 1.323
Immunoglobulin G10.61 ± 3.8979.88 ± 2.498
Immunoglobulin G Subclass 16.20 ± 2.3385.41 ± 1.574
Immunoglobulin G Subclass 23.59 ± 1.6443.74 ± 1.205
Immunoglobulin G Subclass 31.05 ± 0.5510.93 ± 0.510
Immunoglobulin G Subclass 40.394 ± 0.24740.684 ± 0.6286
Immunoglobulin M1.16 ± 0.3651.16 ± 0.642
SecondaryAbsolute Change From Baseline in Immunoglobulin Levels at Day 85

Following immunoglobulin levels were measured: Immunoglobulin A , Immunoglobulin G, Immunoglobulin G Subclass 1, Immunoglobulin G Subclass 2, Immunoglobulin G Subclass 3, Immunoglobulin G Subclass 4, Immunoglobulin M.

Time frame:
Baseline, Day 85
Reported as:
Mean · gram/Liter
Absolute Change From Baseline in Immunoglobulin Levels at Day 85
gram/LiterPlacebo: Double-Blind Treatment PeriodM2951: Double-Blind Treatment Period
Immunoglobulin A-0.07 ± 0.263-0.04 ± 0.133
Immunoglobulin G0.02 ± 1.281-0.30 ± 0.517
Immunoglobulin G Subclass 10.11 ± 0.857-0.15 ± 0.410
Immunoglobulin G Subclass 2-0.13 ± 0.477-0.17 ± 0.404
Immunoglobulin G Subclass 30.07 ± 0.214-0.04 ± 0.209
Immunoglobulin G Subclass 4-0.028 ± 0.1073-0.046 ± 0.2576
Immunoglobulin M-0.04 ± 0.177-0.25 ± 0.255
SecondaryAbsolute B-Cell Levels at Day 85
Time frame:
Day 85
Reported as:
Mean · cells per micro-liter
Absolute B-Cell Levels at Day 85
cells per micro-literPlacebo: Double-Blind Treatment PeriodM2951: Double-Blind Treatment Period
Absolute B-Cell Levels at Day 85243 ± 265.0204 ± 154.0
SecondaryAbsolute Change From Baseline in B-cell Levels at Day 85
Time frame:
Baseline, Day 85
Reported as:
Mean · cells per micro-liter
Absolute Change From Baseline in B-cell Levels at Day 85
cells per micro-literPlacebo: Double-Blind Treatment PeriodM2951: Double-Blind Treatment Period
Absolute Change From Baseline in B-cell Levels at Day 8576 ± 242.011 ± 73.2

Adverse events

Collected over Double-Blind Period: Baseline up to 16 weeks; Open-Label Period: Baseline up to 30 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo: Double-Blind Treatment Period0/32 (0%)0/32 (0%)13/32 (40.6%)
M2951: Double-Blind Treatment Period0/33 (0%)1/33 (3%)17/33 (51.5%)
Placebo/M2951: Open-Label Extension Period0/18 (0%)0/18 (0%)8/18 (44.4%)
M2951/M2951: Open-Label Extension Period0/21 (0%)0/21 (0%)10/21 (47.6%)
Most frequent serious events
Most frequent serious events
EventPlacebo: Double-Blind Treatment PeriodM2951: Double-Blind Treatment PeriodPlacebo/M2951: Open-Label Extension PeriodM2951/M2951: Open-Label Extension Period
Vestibular disorderEar and labyrinth disorders0/321/330/180/21
Vertigo CNS originNervous system disorders0/321/330/180/21
Most frequent other events
Showing 10 of 20
Most frequent other events
EventPlacebo: Double-Blind Treatment PeriodM2951: Double-Blind Treatment PeriodPlacebo/M2951: Open-Label Extension PeriodM2951/M2951: Open-Label Extension Period
NasopharyngitisInfections and infestations0/320/330/183/21
Viral upper respiratory tract infectionInfections and infestations4/323/331/180/21
Alanine aminotransferase increasedInvestigations4/321/331/180/21
Amylase increasedInvestigations3/321/332/180/21
Rheumatoid arthritisMusculoskeletal and connective tissue disorders0/320/332/181/21
NauseaGastrointestinal disorders3/323/330/182/21
VomitingGastrointestinal disorders1/322/330/182/21
Respiratory tract infectionInfections and infestations0/322/330/182/21
Pain in extremityMusculoskeletal and connective tissue disorders0/322/330/182/21
HeadacheNervous system disorders0/322/330/182/21

Baseline characteristics

The Safety Analysis Set included all participants who received at least 1 dose of M2951 or placebo.

Age, Continuous
Age, Continuous(years)Placebo: Double-Blind Treatment PeriodM2951: Double-Blind Treatment PeriodTotal
Mean53.1 ± 12.1953.8 ± 10.7353.4 ± 11.39
Sex: Female, Male
Sex: Female, Male(Participants)Placebo: Double-Blind Treatment PeriodM2951: Double-Blind Treatment PeriodTotal
Female252449
Male7916
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo: Double-Blind Treatment PeriodM2951: Double-Blind Treatment PeriodTotal
Hispanic or Latino112
Not Hispanic or Latino313263
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo: Double-Blind Treatment PeriodM2951: Double-Blind Treatment PeriodTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander011
Black or African American112
White313162
More than one race000
Unknown or Not Reported000
08

Study locations

2 sites
  • U.S. Medical Information
    Billerica, Massachusetts, United States
  • Merck KGaA Communication Center
    Darmstadt, Germany
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2016 to primary completion in Apr 2017, 8 months.

Results were first posted in May 2018, 1 year 1 month after primary completion.

Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 8 months is below that.

Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2016
First posted
May 26, 2016
StartActual
Jul 31, 2016
Primary completionActual
Apr 30, 2017
CompletionActual
Nov 14, 2017
Results first posted
May 30, 2018
Last update
Jul 17, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02784106
Responsible party
Sponsor
First posted
May 26, 2016
Start date
Jul 31, 2016
Primary completion
Apr 30, 2017
Completion
Nov 14, 2017
Results posted
May 30, 2018
Last update
Jul 17, 2018

Study contacts

Medical Responsible
study director · EMD Serono Inc., a business of Merck KGaA, Darmstadt, Germany

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Evobrutinib

Start the discussion